ABTL News Autobytel Inc 10.57 $ABTL Need to Rep

ABTL News Autobytel Inc 10.57 $ABTL

Need to Replace a Boeing 757? Call Airbus
Alexander MacLennan, The Motley Fool - Motley Fool - Tue Nov 11, 5:07PM CST
It's been nearly nine years since Boeing delivered its last Boeing 757, and Airbus Group is looking to take over the Boeing 757 slot with a model of its own. With airline profits growing and the aircraft manufacturing industry booming, what is...
GE: 26.38 (-0.09), DAL: 43.84 (+0.47), AAL: 43.44 (-0.39), BA: 125.36 (+0.72), UAL: 54.66 (-0.17)

American Airlines Crew Votes Against 5-Year Labor Contract - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 4:40PM CST
Flight attendants at American Airlines Group (AAL) voted down a joint five-year labor contract.
SAVE: 78.80 (-0.25), DAL: 43.84 (+0.47), AAL: 43.44 (-0.39), LUV: 39.37 (+0.25)

United Continental, Southwest Airlines October Traffic Rises - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 3:40PM CST
United Continental Holdings (UAL) reported near-flat traffic figures for the month of Oct 2014.
SAVE: 78.80 (-0.25), AAL: 43.44 (-0.39), LUV: 39.37 (+0.25), UAL: 54.66 (-0.17)

4 Safer Ways to Invest in Airlines
Alexander MacLennan, The Motley Fool - Motley Fool - Tue Nov 11, 2:41PM CST
Airline stocks have soared over the past couple years, and there are plenty of reasons to be bullish. Industry consolidation, capacity discipline, and improving demand are boosting profits, yet stock valuations remain low. However, many investors...
AER: 44.16 (-0.01), AAL: 43.44 (-0.39), AYR: 20.46 (+0.16), BA: 125.36 (+0.72)

American Airlines Honors U.S. Service Members And Veterans With Initiatives And Events
PR Newswire - Tue Nov 11, 8:00AM CST
American Airlines will honor service members and veterans of the U.S. Armed Forces this Veterans Day, continuing the work it does every day by committing support to them and their families through a variety of initiatives that work to make a difference in their lives.
AAL: 43.44 (-0.39)

Airlines' traffic, capacity rises
at Investor's Business Daily - Mon Nov 10, 5:55PM CST
American Airlines (AAL) said passenger traffic rose 0.2% as int'l traffic fell 3.7%, weighing on results. Domestic traffic rose 1.3%. Capacity increased 0.5% and passenger load factor fell to 82.2% from 82.5% a year ago. Shares rose 1.5% to 43.83....
AAL: 43.44 (-0.39), LUV: 39.37 (+0.25)

American Airlines positive about new China-U.S. visa policy
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 2:51PM CST

AAL: 43.44 (-0.39)

American Airlines Statement On New U.S. And China Visa Policy
PR Newswire - Mon Nov 10, 2:33PM CST
American Airlines today issued the following statement on the extension of visa validity for travel between the United States and China:
AAL: 43.44 (-0.39)

American Airlines (AAL) Stock Gains Today After Reporting Increased October Traffic
at The Street - Mon Nov 10, 2:10PM CST
American Airlines (AAL) shares are rising after the company reported a 0.2% rise in passenger traffic in October.
AAL: 43.44 (-0.39)

Why Delta Is Still A Great Opportunity For Long-Term Investors
Giorgio Galvan - at Seeking Alpha - Mon Nov 10, 1:36PM CST

DAL: 43.84 (+0.47), AAL: 43.44 (-0.39), UAL: 54.66 (-0.17)

American Airlines' Surprise Labor Issues Again Complicate a Merger
at The Street - Mon Nov 10, 10:49AM CST
American Airlines management hit a stumbling block in a merger that until Sunday seemed to be going according to plan. Labor issues also disrupted the same management team's previous merger.
AAL: 43.44 (-0.39)

American, Southwest's October Traffic, Capacity Rose
at Investor's Business Daily - Mon Nov 10, 10:43AM CST
American Airlines (AAL) and Southwest Airlines (LUV) reported higher traffic for October on Monday as capacity grew. American said passenger traffic rose 0.2% as international traffic fell 3.7%, weighing on results. Domestic traffic rose 1.3%....
AAL: 43.44 (-0.39), LUV: 39.37 (+0.25)

Technical Pointers on Airlines Equities - American Airlines, United Continental Holdings, Gol Linhas Aereas Inteligentes, SkyWest, and Republic Airways Holdings
PR Newswire - Mon Nov 10, 8:20AM CST
Investor-Edge has initiated coverage on the following equities: American Airlines Group Inc. (NASDAQ: AAL), United Continental Holdings Inc. (NYSE: UAL), Gol Linhas Aereas Inteligentes S.A. (NYSE: GOL), SkyWest Inc. (NASDAQ: SKYW), and Republic Airways Holdings Inc. (NASDAQ: RJET). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, November 07, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,573.93, up 0.11% and the NASDAQ Composite closed at 4,632.53, down 0.13%. The S&P 500 finished the session 0.03% higher at 2,031.92. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Industrials Care Sector Index ended the day at 482.39, up 0.10%, with the index advancing 7.33% in the previous three months. Register for your complimentary reports on these five stocks at:
SKYW: 12.33 (-0.03), RJET: 12.99 (-0.10), AAL: 43.44 (-0.39), GOL: 5.20 (+0.39), UAL: 54.66 (-0.17)

American Airlines Group Reports October Traffic Results
PR Newswire - Mon Nov 10, 7:00AM CST
American Airlines Group (NASDAQ: AAL) today reported October 2014 and year-to-date traffic results.
AAL: 43.44 (-0.39)

Flight attendants at American Airlines Group vote down new labor contract
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:41AM CST

AAL: 43.44 (-0.39)


American Airlines crew reject union contract
By JOSH BOAK - AP - Sun Nov 09, 4:43PM CST
WASHINGTON (AP) — Flight attendants at American Airlines rejected a five-year contract Sunday, forcing the world's largest carrier and its union for cabin-crew workers into binding arbitration.
AAL: 43.44 (-0.39)

Delta Air Lines To Profit From Low Oil Price
Alan Longbon - at Seeking Alpha - Sun Nov 09, 8:57AM CST

DAL: 43.84 (+0.47), AAL: 43.44 (-0.39), UAL: 54.66 (-0.17), LUV: 39.37 (+0.25)

Benefits of falling oil prices outweigh harm to energy sector, Barclays says
Seeking Alpha - at Seeking Alpha - Sat Nov 08, 8:25AM CST

BERY: 26.60 (-0.26), FDX: 172.34 (+0.60), MMM: 157.11 (-0.55), KSS: 56.23 (-0.34), HD: 98.14 (-0.02), KR: 58.28 (-0.28), CLX: 101.35 (-0.32), KMB: 113.37 (-0.55), AGCO: 45.11 (-0.13), AXL: 19.98 (+0.05), WMT: 79.01 (-0.43), WMS: 23.36 (+1.14), BWLD: 162.57 (+3.34), UPS: 108.76 (-0.29), VAL: 84.45 (+0.06), SAVE: 78.80 (-0.25), PENN: 14.09 (+0.94), CHH: 53.25 (+0.58), MHK: 143.06 (+0.35), TGT: 65.72 (+0.20), DE: 88.45 (-0.09), AAL: 43.44 (-0.39), DPZ: 91.57 (-0.51), GM: 31.35 (+0.23), SHW: 237.62 (+0.90), BLMN: 21.11 (-0.24), PPG: 205.26 (-1.01)

Why Airfares Aren't Likely to Decline Despite Falling Fuel Prices
at The Street - Fri Nov 07, 8:57AM CST
Despite falling fuel price, airlines are not reducing ticket prices nor are they rushing to open new routes -- something analysts fear.
AAL: 43.44 (-0.39), UAL: 54.66 (-0.17)

The Best Time to Book Your Airline Ticket Has Changed, Says This Study
at The Street - Thu Nov 06, 3:35PM CST
Holiday travel is just around the corner, and Pauline Frommer tells TheStreet’s Jill Malandrino a new study shook up conventional wisdom in the industry.
HLT: 25.21 (+0.07), SAVE: 78.80 (-0.25), DAL: 43.84 (+0.47), AAL: 43.44 (-0.39), JBLU: 12.95 (-0.14), MAR: 77.14 (+0.58), UAL: 54.66 (-0.17), LUV: 39.37 (+0.25)

Robinson to Enhance Aaron's (AAN) RTO Network as CEO - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:45PM CST
Aaron's (AAN) recently announced Robinson as the company's new Chief Executive Officer.
GME: 42.50 (-0.24), BBY: 34.83 (+0.12), AAN: 27.09 (+1.03), MS: 35.79 (-0.09)

New CEO named at Aaron's
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 9:00AM CST

AAN: 27.09 (+1.03)

Aaron's, Inc. Names John W. Robinson III Chief Executive Officer
PR Newswire - Mon Nov 10, 8:01AM CST
Aaron's, Inc. (NYSE: AAN), a lease-to-own retailer specializing in the sales and lease ownership of furniture, consumer electronics, home appliances and accessories, announced today that John W. Robinson III, Executive Vice President of Aaron's, Inc. and Chief Executive Officer of Progressive Leasing, has been named Chief Executive Officer of Aaron's, Inc., effective today. Robinson will also become a member of the Company's Board of Directors. Gil Danielson, who served as interim Chief Executive Officer of Aaron's, Inc., will remain Executive Vice President and Chief Financial Officer.
AAN: 27.09 (+1.03)

Aaron's Enhances Shareholder Wealth, Ups Dividend by 9.5% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 5:20PM CST
Aaron's Inc. (AAN) yesterday announced a 9.5% increase in its quarterly dividend.
RCII: 31.64 (-0.03), KIM: 24.78 (-0.16), KRFT: 57.88 (-0.03), AAN: 27.09 (+1.03)

Aaron's, declares $0.023 dividend
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:55PM CST

AAN: 27.09 (+1.03)

Aaron's, Inc. Directors Raise Dividend by 9.5%
PR Newswire - Wed Nov 05, 3:47PM CST
Aaron's, Inc. (NYSE: AAN), a leader in the sales and lease ownership and specialty retailing of furniture, consumer electronics and home appliances and accessories, today announced that its quarterly dividend rate has been raised to $.023 per share.
AAN: 27.09 (+1.03)

20.0% Return Seen to Date on SmarTrend Aaron's Call (AAN)
Comtex SmarTrend(R) - Tue Nov 04, 5:08PM CST
SmarTrend identified a Downtrend for Aaron's (NYSE:AAN) on July 15th, 2014 at $31.23. In approximately 4 months, Aaron's has returned 20.01% as of today's recent price of $24.98.
AAN: 27.09 (+1.03)

Aaron's Executives Chad Strickland and John Trainor Recognized as Global Leaders
PR Newswire - Tue Nov 04, 1:16PM CST
Aaron's, Inc. (NYSE: AAN), a lease-to-own retailer specializing in the sales and lease ownership of furniture, consumer electronics, home appliances and accessories, announced today that two of Aaron's executives, Chad Strickland and John Trainor, have been recognized by industry peers as global leaders. Chad Strickland, Senior Vice President, Associate Resources at Aaron's, has been named a Global HR Top 10 Breakaway Leader. Aaron's Vice President and Chief Information Officer John Trainor has been awarded the 2014 Georgia CIO of the Year® Award in the Global Category.
AAN: 27.09 (+1.03)

Specialty Retail Equities under Review - Bed Bath and Beyond, Aaron's, Pier 1 Imports, Five Below, and GNC Holdings
PR Newswire - Tue Nov 04, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Bed Bath and Beyond Inc. (NASDAQ: BBBY), Aaron's Inc. (NYSE: AAN), Pier 1 Imports Inc. (NYSE: PIR), Five Below Inc. (NASDAQ: FIVE), and GNC Holdings Inc. (NYSE: GNC). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 03, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,366.24, down 0.14% and the NASDAQ Composite closed at 4,638.91, up 0.18%. The S&P 500 finished the session 0.01% lower at 2,017.81. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Consumer Discretionary Sector Index ended the day at 540.05, up 0.02%, with the index advancing 3.79% in the previous three months. Register for your complimentary reports on these five stocks at:
BBBY: 69.98 (+0.27), PIR: 13.53 (+0.18), GNC: 43.08 (+0.03), AAN: 27.09 (+1.03), FIVE: 40.44 (-0.64)

Progressive Leasing Expands With New Headquarters' Groundbreaking
PR Newswire - Mon Nov 03, 12:21PM CST
Progressive Leasing, a leading virtual lease-to-own company, broke ground today on a six-story building as an expanded project for the fast-growing company's new headquarters. Utah Gov. Gary R. Herbert and Draper City Mayor Troy Walker attended the groundbreaking celebration to promote Utah and Draper as "the best state to grow business."
AAN: 27.09 (+1.03)

Aaron's Shares Down 22.0% Since SmarTrend's Sell Call (AAN)
Comtex SmarTrend(R) - Tue Oct 28, 11:10AM CDT
SmarTrend identified a Downtrend for Aaron's (NYSE:AAN) on July 15th, 2014 at $31.23. In approximately 4 months, Aaron's has returned 22.03% as of today's recent price of $24.35.
AAN: 27.09 (+1.03)

Aaron's (AAN) Flagged As Strong On High Volume
at The Street - Mon Oct 27, 9:16AM CDT
Trade-Ideas LLC identified Aaron's (AAN) as a strong on high relative volume candidate
AAN: 27.09 (+1.03)

Aaron's Beats Q3 Earnings, Shares Fall on FY14 Outlook Cut - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:40AM CDT
Aaron's Inc. (AAN) posted adjusted earnings per share of 39 cents for third-quarter 2014, which came in a penny below the prior-year figure of 40 cents but surpassed the Zacks Consensus Estimate of 38 cents.
DSW: 30.69 (-0.32), GME: 42.50 (-0.24), BBY: 34.83 (+0.12), AAN: 27.09 (+1.03)

Upgrade Alert for Aaron's (AAN)
Comtex SmarTrend(R) - Mon Oct 27, 6:55AM CDT
Aaron's (NYSE:AAN) was upgraded from Market Perform to Outperform at Raymond James today. The stock closed yesterday at $23.27 on volume of 1.1 million shares, above average daily volume of 672,000. In the past 52 weeks, Aaron's share prices have been bracketed by a low of $23.25 and a high of $36.73 and closed yesterday at $23.27, 0% above that low price. Over the past week, the 200-day moving average (MA) has gone down 0.3% while the 50-day MA has declined 0.4%.
AAN: 27.09 (+1.03)

Aaron (AAN) on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 24, 4:14PM CDT

AAN: 27.09 (+1.03)

Aaron's (AAN) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Fri Oct 24, 8:55AM CDT

AAN: 27.09 (+1.03)

Aaron's beats Street 3Q forecasts
Automated Insights - Fri Oct 24, 6:24AM CDT
ATLANTA (AP) _ Aaron's Inc. (AAN) on Friday reported earnings of $9.3 million in its third quarter.
AAN: 27.09 (+1.03)

More on Aaron's Q3
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 6:22AM CDT

AAN: 27.09 (+1.03)

Aaron's beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 6:16AM CDT

AAN: 27.09 (+1.03)

Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 4:30PM CDT

WYN: 79.31 (+1.64), SFE: 19.76 (-0.34), F: 14.37 (+0.37), OCR: 69.01 (+0.28), B: 36.64 (+0.02), SXC: 22.80 (-0.57), VTR: 68.52 (-0.09), UPS: 108.76 (-0.29), DLPH: 70.24 (+0.37), CHH: 53.25 (+0.58), LYB: 88.54 (+0.51), COG: 33.59 (+0.39), SHPG: 202.21 (+1.23), TCB: 15.71 (-0.07), AVY: 47.96 (-0.08), AAN: 27.09 (+1.03), MGLN: 61.39 (+0.91), STT: 77.68 (-0.44), FNFG: 7.51 (+0.06), IMGN: 10.10 (+0.15), EDU: 21.84 (+0.18), BMY: 58.72 (-0.09), DTE: 82.79 (-1.06), LEA: 92.62 (-0.68), MCO: 99.31 (-0.01), FLIR: 32.99 (-0.22), IMS: 24.42 (unch), LPNT: 65.94 (+0.14), ERIC: 11.92 (+0.30), PG: 89.67 (+0.22), IDXX: 152.19 (+5.01), WBC: 101.85 (-0.18), NDAQ: 44.27 (+0.24), CL: 68.47 (-0.08)

AAON's (AAON) CEO Norman Asbjornson on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 10:01PM CST

AAON: 21.13 (+0.29)

AAON declares $0.09 dividend
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 11:44AM CST

AAON: 21.13 (+0.29)

AAON Reports Regular Semi-Annual Cash Dividend
Marketwired - Thu Nov 06, 10:48AM CST
AAON, Inc. (NASDAQ: AAON), today announced at a meeting of the Board of Directors on November 4, 2014, the Board declared a regular semi-annual cash dividend of $0.09 per share. The next dividend will be paid to stockholders of record as of the close of business on December 2, 2014, with a payment date of December 23, 2014.
AAON: 21.13 (+0.29)

AAON misses by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:06AM CST

AAON: 21.13 (+0.29)

AAON Reports Record Sales and Earnings
Marketwired - Thu Nov 06, 6:03AM CST
AAON, Inc. (NASDAQ: AAON) today announced its operating results for the third quarter and nine months ended September 30, 2014.
AAON: 21.13 (+0.29)

Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:30PM CST

CYNI: 2.80 (-0.07), AAP: 144.98 (-0.19), DNOW: 28.27 (+0.82), AAON: 21.13 (+0.29), CNQ: 36.29 (+0.64), HSP: 57.31 (+1.33), CNK: 35.36 (-0.13), AMSC: 1.14 (-0.04), AES: 13.49 (-0.14), MWIV: 155.00 (+0.17), BBG: 13.54 (+0.42), HZNP: 13.05 (+0.13), KATE: 29.39 (-0.31), MITL: 9.76 (-0.05), AEE: 43.31 (-0.01), HSIC: 129.47 (-0.15), HII: 108.28 (-1.28), NAVB: 1.02 (-0.01), CECE: 14.87 (-0.09), AKRX: 34.96 (-1.20), COTY: 18.70 (-0.12), GOLD: 66.06 (+2.19), IT: 84.57 (+0.68), HNR: 3.08 (+0.06), KERX: 15.94 (-0.49), CECO: 5.51 (-0.03), HSC: 20.25 (-0.24), AMRC: 8.03 (-0.13), KLIC: 13.56 (+0.02), GEO: 40.17 (-0.66), AINV: 8.28 (+0.02), BCE: 45.79 (+0.31), AZN: 74.20 (+0.99), BCRX: 10.82 (-0.34), CPN: 24.17 (-0.12), BR: 44.89 (-0.01), FUR: 16.90 (-0.02), LIN: 23.83 (+0.24), LMIA: 13.16 (+0.14), CDW: 32.59 (-0.16), CVC: 18.09 (-0.51), AAWW: 41.61 (-0.14), GNRC: 42.43 (+1.74), MPEL: 26.03 (+0.84), DTV: 86.93 (-0.34), APA: 75.41 (+0.31), CRZO: 51.72 (+1.00), BKCC: 8.93 (-0.02), ERJ: 37.80 (+2.07), AMCX: 61.39 (+0.19), LPI: 18.36 (+0.12), HAIN: 105.55 (-3.66), FSYS: 9.34 (+0.15), GLP: 41.49 (-1.86), AOL: 45.23 (+0.59), FUN: 47.12 (+0.41), BDBD: 9.22 (-0.03)

AAON: Macro Headwinds And Deteriorating Fundamentals
Darspal S Mann - Seeking Alpha - Fri Oct 31, 7:01AM CDT
AAON Inc. ( AAON ) stock has doubled over the last two years, partly on the back of strong demand for air-conditioning and heating equipment for new non-residential construction activity. Looking at the relatively rich valuation of 25 times...
AAON: 21.13 (+0.29)

AAON, Inc. Third Quarter 2014 Sales and Earnings Review Conference Call
Marketwired - Thu Oct 30, 6:01AM CDT
AAON, Inc. (NASDAQ: AAON). A question and answer session will follow a brief presentation by our President and CEO, Norman Asbjornson. The entire call should last about 45 minutes.
AAON: 21.13 (+0.29)

AAON Down 11.3% Since SmarTrend Downtrend Call (AAON)
Comtex SmarTrend(R) - Mon Oct 27, 11:12AM CDT
SmarTrend identified a Downtrend for AAON (NASDAQ:AAON) on July 25th, 2014 at $20.42. In approximately 3 months, AAON has returned 11.34% as of today's recent price of $18.10.
AAON: 21.13 (+0.29)

Shares of AAON Down 13.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Oct 20, 9:51AM CDT
SmarTrend identified a Downtrend for AAON (NASDAQ:AAON) on July 25th, 2014 at $20.42. In approximately 3 months, AAON has returned 13.83% as of today's recent price of $17.59.
AAON: 21.13 (+0.29)

AAON Has Returned 16.7% Since SmarTrend Recommendation (AAON)
Comtex SmarTrend(R) - Tue Oct 07, 4:44PM CDT
SmarTrend identified a Downtrend for AAON (NASDAQ:AAON) on July 25th, 2014 at $20.42. In approximately 2 months, AAON has returned 16.68% as of today's recent price of $17.01.
AAON: 21.13 (+0.29)

Downtrend Call Working As AAON Stock Falls 15.1% (AAON)
Comtex SmarTrend(R) - Tue Sep 30, 11:03AM CDT
SmarTrend identified a Downtrend for AAON (NASDAQ:AAON) on July 25th, 2014 at $20.42. In approximately 2 months, AAON has returned 15.11% as of today's recent price of $17.33.
AAON: 21.13 (+0.29)

11.7% Return Seen to Date on SmarTrend AAON Call (AAON)
Comtex SmarTrend(R) - Tue Sep 16, 9:13AM CDT
SmarTrend identified a Downtrend for AAON (NASDAQ:AAON) on July 25th, 2014 at $20.42. In approximately 2 months, AAON has returned 11.68% as of today's recent price of $18.03.
AAON: 21.13 (+0.29)

AAON Announces Reactivation of Stock Buyback Plan
Marketwire - Mon Aug 25, 6:00AM CDT
AAON, Inc. (NASDAQ: AAON), today announced that its Board of Directors has authorized the Company to resume its stock buyback program adopted in May 2010, having a balance of approximately 1,350,000 shares yet to be repurchased. Under the terms of the Company's plan, purchases may be made from time to time in the open market or through privately negotiated transactions at prevailing market prices, depending on market conditions. All shares purchased will be restored to the status of authorized but unissued stock.
AAON: 21.13 (+0.29)

Comcast and Time Warner Should be Terrified of Google Fiber, Internet Users Should Rejoice
Chris Neiger, The Motley Fool - Motley Fool - Sun Aug 10, 11:00AM CDT
When Google  launched its fiber Internet network, Google Fiber, it was clear that one possible impact would be increased competition in the notoriously noncompetitive home Internet space. And that's exactly what happened. In Kansas City, one...
AAON: 21.13 (+0.29), GOOGL: 561.29 (+3.06), CMCSK: 52.78 (-0.05), TWC: 134.78 (-1.72), GOOG: 550.29 (+2.80)

AAON Reports Sales and Earnings
Marketwire - Thu Aug 07, 6:01AM CDT
AAON, Inc. (NASDAQ: AAON) today announced its operating results for the second quarter and six months ended June 30, 2014.
AAON: 21.13 (+0.29)

AAON, Inc. Second Quarter 2014 Sales and Earnings Review Conference Call
Marketwire - Thu Jul 31, 6:00AM CDT
(July 31, 2014) - AAON, Inc. (NASDAQ: AAON). A question and answer session will follow a brief presentation by our President and CEO, Norman Asbjornson. The entire call should last about 45 minutes.
AAON: 21.13 (+0.29)

AAON LN Series Chiller Is Winner in ACHR News 2014 Dealer Design Awards
Marketwire - Tue Jul 22, 3:54PM CDT
AAON, Inc. (NASDAQ: AAON) was recognized for excellence in product design in the 11th annual Dealer Design Awards Program sponsored by The Air Conditioning Heating & Refrigeration News magazine. An independent panel of contractors acted as judges in the contest that had 92 entries. The company's LN Series Air-Cooled Chiller was the Silver Award Winner in the HVAC Commercial Equipment category. The ACHR News is the leading trade magazine in the heating, ventilating, air conditioning, and refrigeration industries.
AAON: 21.13 (+0.29)

AAON Up 12.4% Since SmarTrend Uptrend Call (AAON)
Comtex SmarTrend(R) - Tue Jul 15, 11:18AM CDT
SmarTrend identified an Uptrend for AAON (NASDAQ:AAON) on April 24th, 2014 at $28.71. In approximately 3 months, AAON has returned 12.40% as of today's recent price of $32.27.
AAON: 21.13 (+0.29)

Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 195.34 (+0.10), GILD: 108.01 (+0.99), ABBV: 63.85 (+0.06), BMY: 58.72 (-0.09)

Galapagos - AbbVie's Best Bet For Staying Market Leader In Rheumatoid Arthritis Post Humira?
SNJBiostoxx - at Seeking Alpha - Tue Nov 11, 2:45PM CST

ABBV: 63.85 (+0.06)

Re-Examining My Bullish Thesis On Walgreen
Alexander J. Poulos - at Seeking Alpha - Tue Nov 11, 1:04PM CST

SHPG: 202.21 (+1.23), PFE: 30.32 (+0.12), AZN: 74.20 (+0.99), ABBV: 63.85 (+0.06), WAG: 67.50 (-0.28)

Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - Tue Nov 11, 10:13AM CST
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 108.01 (+0.99), ACHN: 12.48 (-0.37), MRK: 59.37 (+0.56), ABBV: 63.85 (+0.06), BMY: 58.72 (-0.09)

Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST

JNJ: 108.91 (+0.09), GILD: 108.01 (+0.99), ACHN: 12.48 (-0.37), CNAT: 7.06 (unch), MRK: 59.37 (+0.56), RGLS: 20.47 (-0.44), ABBV: 63.85 (+0.06), BMY: 58.72 (-0.09), ENTA: 43.22 (-0.92)

Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST

VRTX: 117.49 (+0.55), GILD: 108.01 (+0.99), MRK: 59.37 (+0.56), DNDN: 0.15 (-0.03), AZN: 74.20 (+0.99), TEVA: 58.19 (+0.15), ABBV: 63.85 (+0.06), GSK: 45.96 (+0.80), BMY: 58.72 (-0.09), NVS: 92.77 (+0.14)

Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 382.55 (-4.72), YHOO: 49.05 (-0.36), AMZN: 312.01 (+6.90), BIIB: 324.59 (-3.28), VRTX: 117.49 (+0.55), FEYE: 32.85 (+0.46), LNKD: 231.00 (+1.75), EBAY: 54.19 (+0.30), GILD: 108.01 (+0.99), AMGN: 162.42 (-0.67), ABBV: 63.85 (+0.06), REGN: 398.36 (+12.39), CELG: 107.85 (-0.16)

AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST

JNJ: 108.91 (+0.09), GILD: 108.01 (+0.99), ACHN: 12.48 (-0.37), CNAT: 7.06 (unch), MRK: 59.37 (+0.56), RGLS: 20.47 (-0.44), ABBV: 63.85 (+0.06), BMY: 58.72 (-0.09), ENTA: 43.22 (-0.92)

Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST

JNJ: 108.91 (+0.09), GILD: 108.01 (+0.99), ACHN: 12.48 (-0.37), CNAT: 7.06 (unch), MRK: 59.37 (+0.56), LGND: 56.90 (+1.22), RGLS: 20.47 (-0.44), ABBV: 63.85 (+0.06), BMY: 58.72 (-0.09), ENTA: 43.22 (-0.92)

Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST

JNJ: 108.91 (+0.09), GILD: 108.01 (+0.99), ACHN: 12.48 (-0.37), CNAT: 7.06 (unch), LGND: 56.90 (+1.22), RGLS: 20.47 (-0.44), ABBV: 63.85 (+0.06), BMY: 58.72 (-0.09), ENTA: 43.22 (-0.92)

AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting® 2014
PR Newswire - Tue Nov 11, 8:00AM CST
AbbVie (NYSE: ABBV) today announced results from studies in chronic hepatitis C patients with human immunodeficiency virus type 1 (HIV-1) co-infection (TURQUOISE-I) and liver transplant recipients (CORAL-I) at The Liver Meeting®2014.
ABBV: 63.85 (+0.06), ENTA: 43.22 (-0.92)

AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting® 2014
PR Newswire - Tue Nov 11, 7:00AM CST
AbbVie (NYSE:ABBV) announced detailed results from its open-label Phase 2b study, PEARL-I, which demonstrated that 100 percent of genotype 4 (GT4) patients who were new to therapy (n=42/42) or who had failed previous treatment with pegylated interferon (pegIFN) and RBV (n=49/49) achieved sustained virologic response rates at 12 weeks post-treatment (SVR12) after taking AbbVie's investigational treatment with ribavirin (RBV). Additionally, 90.9 percent of patients who were new to therapy achieved SVR12 (n=40/44) after taking the treatment without RBV. These data will be presented today during a poster session at The Liver Meeting® 2014.
ABBV: 63.85 (+0.06), ENTA: 43.22 (-0.92)

Repros Soars on Positive FDA Meeting Regarding Androxa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:20PM CST
Shares of Repros Therapeutics (RPRX) shot up 56.9% following a successful meeting with the FDA regarding Androxal.
BIIB: 324.59 (-3.28), RPRX: 9.50 (+0.28), ABBV: 63.85 (+0.06), AMAG: 34.88 (-0.03)

Shire CEO Looks Ahead To Independent Future
at Investor's Business Daily - Mon Nov 10, 3:46PM CST
Flemming Ornskov has been at Shire for only 18 months, but his term has been quite an adventure already. In January, he closed the Anglo-Irish drugmaker's biggest acquisition, buying U.S. biotech ViroPharma for $4.2 billion. That brought Shire (SHPG)...
BIIB: 324.59 (-3.28), GILD: 108.01 (+0.99), SHPG: 202.21 (+1.23), ABBV: 63.85 (+0.06), CELG: 107.85 (-0.16)

Merck Reports Interim Data on Hepatitis C Virus Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 3:45PM CST
Merck (MRK) presented interim data from a proof-of-concept study on its fixed-dose combination regimen - grazoprevir/elbasvir - in combination with Gilead's Sovaldi.
AGN: 195.34 (+0.10), GILD: 108.01 (+0.99), MRK: 59.37 (+0.56), ABBV: 63.85 (+0.06)

Emergent BioSolutions Beats on Q3 Earnings, Guidance Up - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Mon Nov 10, 11:30AM CST
Emergent BioSolutions reported third quarter earnings of 67 cents per share.
AGN: 195.34 (+0.10), EBS: 24.41 (+0.46), ABAX: 53.50 (+0.56), ABBV: 63.85 (+0.06)

Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - Mon Nov 10, 10:14AM CST
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.91 (+0.09), GILD: 108.01 (+0.99), ACHN: 12.48 (-0.37), MRK: 59.37 (+0.56), ABBV: 63.85 (+0.06), BMY: 58.72 (-0.09)

Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 108.01 (+0.99), ACHN: 12.48 (-0.37), RGLS: 20.47 (-0.44), ABBV: 63.85 (+0.06)

Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST

JNJ: 108.91 (+0.09), GILD: 108.01 (+0.99), CNAT: 7.06 (unch), MRK: 59.37 (+0.56), LGND: 56.90 (+1.22), RGLS: 20.47 (-0.44), ABBV: 63.85 (+0.06), BMY: 58.72 (-0.09), ENTA: 43.22 (-0.92)

Merck's Shortened Hep C Regimens Fall Short of Cure-Rate Goal
at The Street - Sun Nov 09, 5:23PM CST
A triple therapy combining two experimental Merck drugs with Gilead's Sovaldi yielded interim hepatitis C cure rates for ranging from 80% to 87% following six to eight weeks of treatment.
GILD: 108.01 (+0.99), MRK: 59.37 (+0.56), ABBV: 63.85 (+0.06)

Asbury Automotive Earnings Hindsight: Up 13.4% in Last 20 Days (ABG)
Comtex SmarTrend(R) - Mon Nov 10, 8:39AM CST
20 days ago, on October 21st, 2014, Asbury Automotive (NYSE:ABG) reported its earnings. Analysts, on average, expected earnings of $1.08 per share on sales of $1.5 billion. Asbury Automotive actually reported earnings of $1.08 per share on sales of $1.5 billion, beating EPS estimates by $0.00 and missing revenue estimates by $0.5 million. Since the company's report, shares of Asbury Automotive have risen from $64.92 to $73.63, representing a gain of 13.4% in the past 20 days.
ABG: 73.87 (+0.33)

Analyst Sees Clear Lane For AutoNation, Other Dealers
at Investor's Business Daily - Wed Oct 29, 12:35PM CDT
A new report from Sterne Agee offered a bullish outlook for car dealers Wednesday morning, a day after No. 1 U.S. dealer AutoNation (AN) topped quarterly earnings views and the same day Penske Automotive Group (PAG) met EPS estimates and announced a...
LAD: 76.81 (+0.94), KMX: 55.74 (-0.34), ABG: 73.87 (+0.33), PAG: 47.42 (+0.32), AN: 57.87 (-0.03)

ELEAD1ONE Hires Aaron Baldwin as Director of Digital Marketing
Business Wire - Tue Oct 28, 10:00AM CDT
ELEAD1ONE today announced the appointment of Aaron Baldwin to the position of Director of Digital Marketing of ELEAD1ONE, a division of Data Services, L.L.C. In his role, Aaron will be responsible for the daily operations, product strategy and performance of ELEAD Digital. ELEAD Digital develops, supports, and implements key digital marketing products for their dealer clients, including responsive websites, custom email marketing campaigns, SEO and strategic business development with cutting-edge market leaders.
ABG: 73.87 (+0.33)

AutoNation - bull vs. bear case after Q3 beat
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 8:10AM CDT

LAD: 76.81 (+0.94), ABG: 73.87 (+0.33), SAH: 25.47 (+0.34), AN: 57.87 (-0.03)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 4:42PM CDT

MXWL: 11.14 (+0.14), AMZN: 312.01 (+6.90), GIMO: 14.53 (-0.11), UFCS: 29.83 (-0.42), ABG: 73.87 (+0.33), P: 18.59 (+0.09), SYNA: 62.47 (+0.36), RUBI: 12.60 (+0.10), VTAE: 16.48 (+0.09), KLAC: 80.19 (-0.32)

Asbury Automotive Group Appoints David Hult as its Executive Vice President and Chief Operating Officer
PR Newswire - Thu Oct 23, 4:36PM CDT
Asbury Automotive Group, Inc. (NYSE: ABG), (the "Company" one of the largest automotive retail and service companies in the U.S., announced that David W. Hult will join the company as its Executive Vice President and Chief Operating Officer effective November 3, 2014.
ABG: 73.87 (+0.33)

Downgrade Alert for Asbury Automotive (ABG)
Comtex SmarTrend(R) - Thu Oct 23, 7:03AM CDT
Asbury Automotive (NYSE:ABG) was downgraded from Buy to Hold at Craig-Hallum today. The stock closed yesterday at $61.46 on volume of 694,000 shares, above average daily volume of 463,000. Asbury Automotive share prices have moved between a 52-week high of $73.35 and a 52-week low of $45.31 and closed yesterday at 36% above that low price at $61.46 per share. The 200-day and 50-day moving averages have moved 0.27% higher and 0.41% lower over the past week, respectively.
ABG: 73.87 (+0.33)

Asbury Automotive Set to Possibly Rebound After Yesterday's Selloff of 5.33%
Comtex SmarTrend(R) - Wed Oct 22, 5:20PM CDT
Asbury Automotive (NYSE:ABG) traded in a range yesterday that spanned from a low of $61.31 to a high of $64.72. Yesterday, the shares fell 5.3%, which took the trading range below the 3-day low of $62.79 on volume of 694,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ABG: 73.87 (+0.33)

Sonic Automotive Q3 Earnings & Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 8:30AM CDT
Sonic Automotive Inc. (SAH) reported third-quarter 2014 adjusted earnings per share of 46 cents, which was in line with the year-ago number
ABG: 73.87 (+0.33), CVGI: 6.53 (-0.07), SAH: 25.47 (+0.34), RUSHA: 36.75 (-0.23)

Asbury Automotive Group (ABG) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Oct 21, 8:55AM CDT

ABG: 73.87 (+0.33)

More on Asbury Automotive Group's Q3
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 6:28AM CDT

ABG: 73.87 (+0.33)

Asbury Automotive matches Street 3Q forecasts
Automated Insights - Tue Oct 21, 6:21AM CDT
DULUTH, Ga. (AP) _ Asbury Automotive Group Inc. (ABG) on Tuesday reported third-quarter earnings of $32.5 million.
ABG: 73.87 (+0.33)

Asbury Automotive beats by $0.01, revenue in-line
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 6:05AM CDT

ABG: 73.87 (+0.33)

Asbury Automotive Group Announces Record 2014 Third Quarter Financial Results
PR Newswire - Tue Oct 21, 6:00AM CDT
Asbury Automotive Group, Inc. (NYSE: ABG), one of the largest automotive retail and service companies in the U.S., today reported income from continuing operations for the third quarter of 2014 of $32.4 million, or $1.08 per diluted share, versus adjusted income from continuing operations in the third quarter of 2013 of $28.3 million, or $0.91 per diluted share, a 19% increase per diluted share. There were no adjustments for the third quarter of 2014, see attached reconciliation for reported adjustments related to the third quarter of 2013. Net income for the third quarter of 2014 was $32.5 million, or $1.08 per diluted share, compared to $22.7 million, or $0.73 per diluted share in the prior year period.
ABG: 73.87 (+0.33)

Asbury Automotive Increases Total Share Repurchase Authorization To $200 Million; Amends Credit Facility To Increase Capacity For Share Repurchases
PR Newswire - Fri Oct 17, 6:30AM CDT
Asbury Automotive Group, Inc. (NYSE: ABG), one of the largest automotive retail and services companies in the U.S., today announced that its Board of Directors has increased the size of the Company's share repurchase authorization. With this increase, the Company now has the authority to repurchase up to $200 million of the Company's common stock. During the third quarter of 2014, the Company repurchased $39.8 million of its common stock and from January 1, 2014 through September 30, 2014, the Company repurchased $69.2 million of its common stock. As of September 30, 2014, the Company had approximately 29.8 million shares outstanding.
ABG: 73.87 (+0.33)

Asbury Automotive: Improving Market And Business Expansion To Drive Earnings Growth
InvestAlike - at Seeking Alpha - Wed Oct 15, 4:52PM CDT

ABG: 73.87 (+0.33)

Penske Automotive's Sales and Dealership Network Expand - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 1:00PM CDT
On Oct 10, 2014, we issued an updated research report on Penske Automotive Group Inc. (PAG)
ABG: 73.87 (+0.33), TM: 119.14 (+1.17), PAG: 47.42 (+0.32)

Lithia Motors (LAD) Slumps: LAD Falls 20.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 7:46AM CDT
Lithia Motors's shares dropped 20% yesterday , continuing the recent volatility in the past one-month time frame.
LAD: 76.81 (+0.94), CRMT: 48.10 (-0.59), ABG: 73.87 (+0.33), PAG: 47.42 (+0.32)

Car Dealer Stocks Crash On Lithia's Weak Used Prices
at Investor's Business Daily - Mon Oct 13, 2:35PM CDT
A drop in used-car values damaged third-quarter earnings at Lithia Motors (LAD) and caused it to reduce per-share earnings guidance well below Wall Street views, the Oregon-based auto dealer said Monday, sending the IBD 50 stock crashing 19%. Other...
KMX: 55.74 (-0.34), LAD: 76.81 (+0.94), GPI: 87.23 (+0.69), ABG: 73.87 (+0.33), PAG: 47.42 (+0.32), AN: 57.87 (-0.03)

Stocks Off Lows In Volatile Trade; Auto Retailers Slide
at Investor's Business Daily - Mon Oct 13, 11:04AM CDT
Stocks were lower Monday, but they have come well off their session lows near halftime. The Nasdaq fell 0.4% and the S&P 500 lost 0.3%. Earlier in the day, they were off by as much as 1.3% and 0.8%, respectively. The S&P 500 climbed back above the...
LAD: 76.81 (+0.94), SWKS: 60.97 (unch), ABG: 73.87 (+0.33), MCHP: 43.38 (-0.11), CP: 210.01 (+1.08), PAG: 47.42 (+0.32), CSX: 36.71 (+0.15), AVGO: 86.16 (+0.25), AN: 57.87 (-0.03)

Roka Bioscience (ROKA) in Focus: Stock Surges 19.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:11AM CST
Roka Bioscience, Inc. (ROKA) was a big mover last session, as the company saw its shares rise over 19% on the day.
ABMD: 33.09 (+0.10), ROKA: 3.56 (-0.02), EW: 124.79 (+0.19), ANGO: 16.96 (unch)

OTC Daily Alert Stock Watch - ABIOMED, Inc. (NASDAQ: ABMD)
WorldStockWire - Mon Nov 10, 12:30PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ABMD: 33.09 (+0.10)

Volcano Posts Narrower-than-Expected Q3 Loss, Guides Low - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:10AM CST
Despite Volcano (VOLC) provided disappointing revenue guidance for 2014 on account of expected negative foreign exchange impact, management expects accelerated profitability over the near term.
ABMD: 33.09 (+0.10), VOLC: 11.14 (+0.60), EW: 124.79 (+0.19), ANGO: 16.96 (unch)

Strength Seen in DexCom (DXCM): Stocks Gains 14.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:46AM CST
DexCom (DXCM) was a big mover last session, with shares rising over 14% on the day.
ABMD: 33.09 (+0.10), DXCM: 53.14 (-0.36), EW: 124.79 (+0.19), ANGO: 16.96 (unch)

VYCOR: "On the Cusp of the Next Big Healthcare Trend"
ACCESSWIRE - Mon Nov 10, 8:23AM CST
Vycor: "On the Cusp of the Next Big Healthcare Trend"
MDVN: 107.29 (-1.66), ABMD: 33.09 (+0.10), JNJ: 108.91 (+0.09), AMGN: 162.42 (-0.67), EXAS: 22.45 (-0.15), ARAY: 7.02 (+0.12), HOLX: 26.61 (+0.06), PBYI: 240.35 (-4.44)

Update: Abiomed's Q2 Fiscal 2015 Earnings Remained Impressive
Andy Batts - at Seeking Alpha - Sat Nov 08, 4:40PM CST

ABMD: 33.09 (+0.10)

Hologic Beats Q4 Earnings, Sales as All Segments Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 1:50PM CST
Hologic (HOLX) entered into an amended license agreement with Roka Bioscience, which earned a one-time revenue benefit of $20.1 million for Hologic
ABMD: 33.09 (+0.10), DXCM: 53.14 (-0.36), ANGO: 16.96 (unch), HOLX: 26.61 (+0.06)

Thoratec Q3 Earnings & Revenues Lag Estimates, Down Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:00AM CST
Following the earnings release, shares of Thoratec Corp. (THOR) declined approximately 3.5% to close at $26.10 yesterday.
ABMD: 33.09 (+0.10), CYNO: 26.15 (+0.74), THOR: 27.77 (+0.47), ANGO: 16.96 (unch)

Abiomed (ABMD) Upgraded From Hold to Buy
at The Street - Fri Nov 07, 8:07AM CST
Abiomed (ABMD) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.
ABMD: 33.09 (+0.10)

Foundation Medicine Slumps: FMI Tumbles 9.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:59AM CST
Foundation Medicine has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ABMD: 33.09 (+0.10), DXCM: 53.14 (-0.36), FMI: 24.48 (-0.23), ANGO: 16.96 (unch)

Mindray Medical Q3 Earnings in Line, 2014 View Lowered - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 2:07PM CST
Mindray Medical International Limited (MR) slashed its 2014 financial guidance in the face of increasing uncertainties in currency and other macro developments that could impact its performance in certain key markets.
ABMD: 33.09 (+0.10), FLDM: 29.52 (+0.52), ANGO: 16.96 (unch), MR: 30.86 (+0.26)

Abiomed Tops Q2 Earnings, Revenues; FY15 Sales View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 12:10PM CST
Abiomed Inc. (ABMD) reported second-quarter fiscal 2015 earnings of 9 cents per share, outshining the Zacks Consensus Estimate of 2 cents.
ABMD: 33.09 (+0.10), FLDM: 29.52 (+0.52), BEAT: 8.27 (+0.07), ANGO: 16.96 (unch)

Downgrade Alert for ABIOMED (ABMD)
Comtex SmarTrend(R) - Mon Nov 03, 7:58AM CST
ABIOMED (NASDAQ:ABMD) was downgraded from Buy to Neutral at BTIG today. The stock closed yesterday at $32.79 on volume of 1.3 million shares, above average daily volume of 260,000. ABIOMED share prices have moved between a 52-week high of $32.99 and a 52-week low of $20.29 and closed yesterday at 62% above that low price at $32.79 per share. In the last five trading sessions, the 50-day moving average (MA) has climbed 1.1% while the 200-day MA has remained constant.
ABMD: 33.09 (+0.10)

Abiomed ups earnings 246% in FQ2
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 8:18AM CDT

ABMD: 33.09 (+0.10)

Nasdaq stocks posting largest percentage increases
AP - Thu Oct 30, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
IMDZ: 29.94 (-0.21), ABMD: 33.09 (+0.10), BGFV: 12.99 (+0.06), RDCM: 9.30 (+0.19), AMED: 24.95 (-0.19), MRCY: 13.42 (-0.33), OMER: 19.05 (+1.56), ESBF: 18.91 (+0.08), EVOK: 6.86 (+0.10), IQNT: 17.70 (+0.28), KONA: 23.17 (+0.05), TQNT: 22.31 (+0.01), LAKE: 12.72 (-0.26), SAJA: 6.25 (+0.65)

Ocwen Financial Climbs Despite Earnings Shortfall
at The Street - Thu Oct 30, 4:20PM CDT
ABIOMED, Inc. (NASDAQ:ABMD), Calix Inc (NYSE:CALX) and Ocwen Financial Corp (NYSE:OCN) are today's top-gaining billionaire stock picks. In the red this Thursday are Yamana Gold Inc. (NYSE:AUY), Wes...
ABMD: 33.09 (+0.10), CALX: 11.31 (-0.07), OCN: 23.04 (+1.08), AUY: 3.86 (+0.20), WSTL: 1.35 (-0.03)

ABIOMED's (ABMD) CEO Mike Minogue on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 2:07PM CDT

ABMD: 33.09 (+0.10)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 11:47AM CDT

ABMD: 33.09 (+0.10), CALX: 11.31 (-0.07), LOJN: 2.70 (+0.01), ALU: 3.19 (+0.02), CDTI: 2.46 (-0.18), NKA: 4.53 (-0.30), ARAY: 7.02 (+0.12), GLUU: 3.86 (+0.07), PDII: 1.78 (+0.03), OMER: 19.05 (+1.56), ESBF: 18.91 (+0.08), CRNT: 1.10 (-0.04), CBDE: 0.96 (+0.03), PRXL: 54.86 (+0.36), BWEN: 6.45 (-0.10), ALDX: 7.51 (-0.40), BBSI: 23.10 (-1.18), LAKE: 12.72 (-0.26), OPHC: 0.94 (+0.02), WTW: 25.90 (+0.28)

Abiomed tops Street 2Q forecasts
Automated Insights - Thu Oct 30, 7:28AM CDT
DANVERS, Mass. (AP) _ Abiomed Inc. (ABMD) on Thursday reported profit of $3.8 million in its fiscal second quarter.
ABMD: 33.09 (+0.10)

Arbor Realty Trust's (ABR) CEO, Ivan Kaufman on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 11:42AM CST

ABR: 7.00 (-0.02)

Strong quarter for Arbor Realty
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:06AM CST

ABR: 7.00 (-0.02)

Arbor Realty Trust, Inc. declares $0.13 dividend
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 7:51AM CST

ABR: 7.00 (-0.02)

Arbor Realty Trust Reports Third Quarter 2014 Results and Declares Common Stock Dividend
GlobeNewswire - Fri Nov 07, 7:37AM CST
Third Quarter Highlights:
ABR: 7.00 (-0.02), ABRN: 24.38 (-0.03)

Arbor Realty Trust beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 7:03AM CST

ABR: 7.00 (-0.02)

What To Hold: 3 Hold-Rated Dividend Stocks SPH, SIR, ABR
at The Street - Thu Nov 06, 9:31AM CST
These 3 dividend stocks are rated a Hold by TheStreet
ABR: 7.00 (-0.02), SIR: 24.26 (+0.02), SPH: 44.47 (unch)

Arbor Realty Trust Declares Preferred Stock Dividends
GlobeNewswire - Mon Nov 03, 7:37AM CST
Arbor Realty Trust, Inc. (NYSE:ABR), today announced that its Board of Directors has declared cash dividends on the Company's Series A, Series B and Series C cumulative redeemable preferred stock reflecting accrued dividends from September 1, 2014 through November 30, 2014. The dividends are payable on December 1, 2014 to preferred shareholders of record on November 15, 2014. The Company will pay total dividends of $0.515625, $0.484375 and $0.53125 per share on the Series A, Series B and Series C preferred stock, respectively.
ABR: 7.00 (-0.02)

Artisan Partners (APAM) Falls: Stock Goes Down 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:43AM CDT
Shares of Artisan Partners fell over 5% last session and witnessed negative revision in current year estimates in the past few weeks suggest a close watch of the firm in the near future.
BAM: 49.58 (-0.73), ABR: 7.00 (-0.02), APAM: 48.78 (+0.49)

3 Hold-Rated Dividend Stocks: TCPC, ABR, HCAP
at The Street - Mon Oct 27, 10:31AM CDT
These 3 dividend stocks are rated a Hold by TheStreet
ABR: 7.00 (-0.02), TCPC: 17.04 (-0.15), HCAP: 11.99 (-0.39)

Arbor Realty Trust Schedules Third Quarter 2014 Earnings Conference Call
GlobeNewswire - Fri Oct 24, 7:00AM CDT
Arbor Realty Trust, Inc. (NYSE:ABR), today announced that it is scheduled to release third quarter 2014 financial results before market open on Friday, November 7, 2014. The Company will also host a conference call to review the results at 10:00 am ET on November 7th.
ABR: 7.00 (-0.02)

'Mad Money' Lightning Round: Take EOG Resources Over Chesapeake Energy
at The Street - Thu Oct 23, 5:00AM CDT
Cramer prefers Celgene over Kite Pharma, General Electric over Babcock & Wilcox and sees a red flag over Ellington Financial.
SD: 3.78 (+0.09), GE: 26.38 (-0.09), ABR: 7.00 (-0.02), EMES: 79.88 (-1.42), AMGN: 162.42 (-0.67), CELG: 107.85 (-0.16), BWC: 30.15 (-0.25), KITE: 42.47 (-0.39), CHK: 23.43 (+0.53), SLW: 18.69 (+0.73), EFC: 21.86 (-0.11), EOG: 98.75 (+0.25), APA: 75.41 (+0.31)

Cramer's Lightning Round - It Is Hard To Feel Good About SandRidge (10/22/14)
SA Editor Miriam Metzinger - Seeking Alpha - Thu Oct 23, 3:46AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday October 22. Bullish Calls: Celgene (NASDAQ: CELG ): "It usually goes down after it reports, and it has a lot of the pipeline." EOG...
SD: 3.78 (+0.09), BWC: 30.15 (-0.25), ABR: 7.00 (-0.02), EMES: 79.88 (-1.42), KITE: 42.47 (-0.39), SLW: 18.69 (+0.73), EFC: 21.86 (-0.11), EOG: 98.75 (+0.25), AMGN: 162.42 (-0.67), APA: 75.41 (+0.31), CELG: 107.85 (-0.16), APC: 93.01 (+0.67)

Jim Cramer's 'Mad Money' Recap: The Machines Are Ruining the Market
at The Street - Wed Oct 22, 7:25PM CDT
The machines focus on the bad news and ignores the good, but smart investors can now move in and buy, buy, buy.
SD: 3.78 (+0.09), KO: 42.51 (+0.12), KMI: 38.54 (+0.04), MNST: 107.01 (-0.75), GE: 26.38 (-0.09), EMES: 79.88 (-1.42), ABR: 7.00 (-0.02), HON: 96.98 (-0.29), GMCR: 154.69 (-0.68), AMGN: 162.42 (-0.67), BA: 125.36 (+0.72), CELG: 107.85 (-0.16), YHOO: 49.05 (-0.36), BWC: 30.15 (-0.25), KITE: 42.47 (-0.39), CHK: 23.43 (+0.53), CMG: 656.65 (+7.79), SLW: 18.69 (+0.73), EOG: 98.75 (+0.25), EFC: 21.86 (-0.11), APA: 75.41 (+0.31), GOOGL: 561.29 (+3.06), AAPL: 109.70 (+0.87), DOW: 49.52 (+0.04), BABA: 114.54 (-4.61)

3 Hold-Rated Dividend Stocks: ABR, SXCP, MMLP
at The Street - Wed Oct 15, 10:30AM CDT
These 3 dividend stocks are rated a Hold by TheStreet
MMLP: 34.00 (-0.06), SXCP: 25.76 (+0.26), ABR: 7.00 (-0.02)

What To Hold: 3 Hold-Rated Dividend Stocks ABR, HCAP, UMH
at The Street - Mon Oct 06, 10:30AM CDT
These 3 dividend stocks are rated a Hold by TheStreet
ABR: 7.00 (-0.02), HCAP: 11.99 (-0.39), UMH: 9.96 (-0.04)

What To Hold: 3 Hold-Rated Dividend Stocks NSLP, ABR, NRP
at The Street - Thu Sep 25, 10:30AM CDT
These 3 dividend stocks are rated a Hold by TheStreet
NRP: 12.75 (-0.27), ABR: 7.00 (-0.02), NSLP: 16.50 (-1.45)

3 Hold-Rated Dividend Stocks: ABR, BDCV, DSWL
at The Street - Wed Sep 03, 10:30AM CDT
These 3 dividend stocks are rated a Hold by TheStreet
ABR: 7.00 (-0.02), BDCV: 5.05 (+0.02), DSWL: 2.13 (-0.02)

What To Hold: 3 Hold-Rated Dividend Stocks APTS, ABR, RAS
at The Street - Wed Aug 20, 10:30AM CDT
These 3 dividend stocks are rated a Hold by TheStreet
ABR: 7.00 (-0.02), APTS: 8.72 (-0.02), RAS: 7.28 (unch)

3 Hold-Rated Dividend Stocks: ABR, MITT, RAS
at The Street - Mon Aug 11, 10:30AM CDT
These 3 dividend stocks are rated a Hold by TheStreet
ABR: 7.00 (-0.02), MITT: 19.16 (-0.02), RAS: 7.28 (unch)

Arbor Realty Trust, Inc. Announces Pricing of Public Offering of 7.375% Senior Notes Due 2021
GlobeNewswire - Mon Aug 04, 3:35PM CDT
Arbor Realty Trust, Inc. (the "Company" (NYSE:ABR) announced today that it has priced its public offering of $35.0 million aggregate principal amount of its 7.375% Senior Notes due 2021 (the "Additional Notes" for gross proceeds of $33.88 million. The offering was made pursuant to a reopening of its existing series of such notes (the "Existing Notes" . The Company granted the underwriters a 30-day option to purchase up to an additional $5.25 million aggregate principal amount of notes to cover over-allotments, if any. The Existing Notes are listed on the NYSE under the symbol "ABRN" and the Company intends to file an application to list the Additional Notes on the NYSE under the same symbol.
ABR: 7.00 (-0.02)

Abbott Laboratories' (ABT) Presents at Credit Suisse Healthcare Conference -- Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 4:19PM CST

ABT: 44.25 (+0.16)

DexCom Scales 52-Week High on Product Pipeline Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 1:10PM CST
Impressive third-quarter 2014 results, recent FDA approvals for its new products along with a robust product pipeline contribute to the growth trajectory of DexCom, Inc. (DXCM), creating good momentum for 2015 as well.
ABT: 44.25 (+0.16), JNJ: 108.91 (+0.09), DXCM: 53.14 (-0.36), MDT: 68.99 (+0.28)

Global Syringes (Disposable and Reusable) Industry
PR Newswire - Tue Nov 11, 10:17AM CST
This report analyzes the worldwide markets for Syringes (Disposable and Reusable) in US$ Thousands by the following Product Segments: Anesthesia Syringes, Angiographic Syringes, Blood Gas Syringes, Catheter Syringes, Dental Syringes, Ear Syringes, Hypodermic Syringes (Prefilled Syringes, & Other Hypodermic Syringes), Insulin Syringes, Intraligamentary Syringes, and Irrigating Syringes. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 109 companies including many key and niche players such as -
ABT: 44.25 (+0.16)

U.S. Market for Peripheral Vascular Devices and Accessories Executive Summary: By 2020, the U.S. market for peripheral vascular devices will be worth over $6 billion
M2 - Tue Nov 11, 6:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rwwd3/u_s_market_for) has announced the addition of the "U.S. Market for Peripheral Vascular Devices and Accessories (Executive Summary)" report to their offering. The peripheral vascular device market includes stents, percutaneous transluminal angioplasty (PTA) balloon catheters, atherectomy devices, chronic total occlusion devices, stent grafts, surgical grafts, arteriovenous (AV) access thrombectomy devices, inferior vena cava filters, catheters, guidewires, introducer sheaths, vascular closure devices and transcatheter embolization devices. These devices can be used for treating either coronary arterial or peripheral arterial disease (PAD), but only those devices used for peripheral procedures are included in this report. Older individuals and those who are obese have a higher risk of developing PAD. As result of a general increase in peripheral procedures and the development of new lower-limb treatments, the market for products such as stents and stent grafts will grow rapidly in the U.S. over the forecast period. Peripheral artery disease (PAD) remains a significantly under treated condition in the U.S and PAD is the leading cause of leg amputation. These factors will continue to drive growth in the peripheral vascular device market. In particular, the peripheral stent market is projected to grow over the forecast period. However, intense competition has led to price erosion and market penetration has moderated this once high growth segment. The launch of new technologies, including drug-eluting stents, will generate marginal revenues and only one company has sought FDA approval. In contrast, significant investments and acquisitions have taken place in the efforts of bringing the first drug-eluting balloon to the market, with Medtronic and C. R. Bard in a tight race to gain approval. Scope - Competitor Analysis - Identified Strategic Opportunities - Market Overview by Segment - Trend Analysis by Segment - Market Drivers & Limiters - Mergers & Acquisitions - Customer Feedback and Market Monitoring Main Segments Included: - Peripheral Vascular Stent Market - PTA Balloon Catheter Market - Atherectomy Device Market - Chronic Total Occlusion (CTO) Device Market - Embolic Protection Device Market - Stent Graft Market - Surgical Graft Market - AV Access Thrombectomy Device Market - Inferior Vena Cava Filter Market - Diagnostic and Interventional Catheter Market - Diagnostic and Interventional Guidewire Market - Introducer Sheath Market - Vascular Closure Device Market - Transcatheter Embolization Device Market Companies Mentioned - ALN International Inc. - Abbott Laboratories - AccessClosure - AngioDynamics - AngioScore - Angiotech - Argon Medical - Arstasis - Artegraft - Asahi Intecc USA - Atrax - Atrium Medical - B. Braun - Boston Scientific - C. R. Bard - Cardiovascular Systems Inc - Cardiva CeloNova Biosciences - Cook Medical - Cordis - Covidien - Endologix - IDEV Technologies - LeMaitre Vascular - MEDRAD - Maquet - Marine Polymer Technologies - Medtronic - Morris Innovative - Penumbra - Pfizer For more information visit http://www.researchandmarkets.com/research/3r...market_for About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BSX: 13.41 (-0.04), ABT: 44.25 (+0.16), MDT: 68.99 (+0.28), CSII: 29.76 (-0.26), LMAT: 7.13 (-0.03)

Look for Shares of Abbott Laboratories to Potentially Pullback after Yesterday's 1.66% Rise
Comtex SmarTrend(R) - Mon Nov 10, 4:03PM CST
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $43.17 to a high of $44.10. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $43.99 on volume of 5.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ABT: 44.25 (+0.16)

DexCom G4 Platinum Software Gains FDA Nod, Shares Surge - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 1:54PM CST
Following the announcement, shares of DexCom, Inc. (DXCM) shot up nearly 14.12% to close at $50.93 in the last trading session.
ABT: 44.25 (+0.16), JNJ: 108.91 (+0.09), DXCM: 53.14 (-0.36), MDT: 68.99 (+0.28)

Abbott Looks Overvalued On A Fundamental Basis
Stock Traders Daily - at Seeking Alpha - Fri Nov 07, 9:51AM CST

ABT: 44.25 (+0.16)

5 Things AbbVie Inc.'s Management Wants You to Know
Keith Speights, The Motley Fool - Motley Fool - Thu Nov 06, 11:38AM CST
Another quarter for AbbVie , another blow-out. The company announced strong third-quarter results last Friday. AbbVie's storyline behind those earnings, though, is probably more important than the numbers themselves. Here are five things the...
ABT: 44.25 (+0.16), GILD: 108.01 (+0.99), ABBV: 63.85 (+0.06)

Global Polymerase Chain Reaction (PCR) Market 2014-2018: Key Vendors are Abbott Laboratories, Agilent Technologies, Bio-Rad Laboratories, GE Healthcare and Thermo Fisher Scientific
M2 - Thu Nov 06, 5:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/slnt9m/global_polymerase) has announced the addition of the "Global Polymerase Chain Reaction (PCR) Market 2014-2018" report to their offering. Polymerase Chain Reaction (PCR) is a technique of molecular genetics, which allows amplification and analysis of nucleic acid. It is very precise, specific and accurate technique used to amplify a specific DNA target from a mixture of DNA molecules. It is used in a wide array of applications in research and diagnosis, including genetic engineering, cloning, sequencing, diagnosis, genotyping, and many other areas. Advances in PCR technology and tools provide high reproducibility within a short period of time. Depending on the requirement, PCR involves different types of reagents, consumables and instruments to process the sample. Advanced software helps to analyze the data generated from the sample processing. The analysts forecast the Global Polymerase Chain Reaction market to grow at a CAGR of 9.19 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Polymerase Chain Reaction market for the period 2014-2018. To calculate the market size, the report considers revenue generated from sales of products used in PCR. The products considered within the scope of the report are PCR reagents and consumables, instruments, and software and services, which are required to perform PCR. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Product 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Affimetrix - Agilent Technologies - BD - Bio-Rad Laboratories - Cepheid - Danaher - Eppendorf - F. Hoffmann-La Roche - Fluidigm - GE Healthcare - Harvard Bioscience - Illumin - PerkinElmer - Promega - Qiagen - RainDanceTechnologies - Sigma-Aldrich - Takara Bio - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/sl...polymerase
ABT: 44.25 (+0.16), A: 41.66 (+0.13), CPHD: 52.50 (-0.30), DHR: 81.41 (+0.12), PKI: 43.99 (-0.03)

Global Drug Abuse Testing Market Outlook 2018 - Increase in Number of Collaborations and M&A
M2 - Thu Nov 06, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/dtmmdp/global_drug_abuse) has announced the addition of the "Global Drug Abuse Testing Market 2014-2018" report to their offering. The Global Drug Abuse Testing market to grow at a CAGR of 4.71% over the period 2013-2018 To calculate the market size, the report considers the revenue generated from sales of drug abuse testing solutions, which includes drug abuse testing kits and systems. The technologies primarily considered in the report are immunoassay and chromatography. One of the major trends upcoming in the market is the increase in the number of collaborations and M&A in the market. This strategy helps vendors to expand their portfolio as well as improve the quality and performance of their products. According to the report, the rising consumption of illicit drugs is a major driver in the Global Drug Abuse Testing market as the use of illicit drugs in developed as well as in developing countries is increasing worldwide. Further, the report states that one of the key challenges that the market faces is the inability of drug abuse testing products to detect low-dose designer drugs. The detection of designer drugs such as ecstasy, Rohypnol, and LSD is very difficult. Key Vendors - Bio-Rad Laboratories - Danaher - F. Hoffmann-La Roche - Siemens - Thermo Fisher Scientific Other Prominent Vendors - Abbott Laboratories - Agilent Technologies - Alere - Biomedical Diagnostics - Branan Medical - OraSure Technologies - PerkinElmer - Psychemedics - Quest Diagnostic - Randox Laboratories - Sigma-Aldrich - Sonic Healthcare - Waters Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Overview - Market Landscape - Market Segmentation by Technique - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/dt...drug_abuse
PMD: 14.83 (-0.13), ABT: 44.25 (+0.16), A: 41.66 (+0.13), DHR: 81.41 (+0.12), PKI: 43.99 (-0.03), OSUR: 9.24 (+0.07)

Abbott to Present at Credit Suisse 2014 Healthcare Conference
PR Newswire - Tue Nov 04, 8:00AM CST
Abbott (NYSE: ABT) will participate in the Credit Suisse 2014 Healthcare Conference on Tuesday, Nov. 11, 2014. Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a formal presentation on the company beginning at 12 p.m. Central time.
ABT: 44.25 (+0.16)

3D Bioprinting Technology Developed by RBCC Partner n3D Biosciences Helps Researchers Create a Better In Vitro Breast Cancer Model
Business Wire - Mon Nov 03, 4:30AM CST
A Texas Medical Center research team has made a stunning breakthrough in breast cancer research using revolutionary 3D bioprinting technology being marketed and developed by Nano3D Biosciences (n3D), a joint venture partner of Rainbow Coral Corp. (OTCBB:RBCC).
ABT: 44.25 (+0.16), BIIB: 324.59 (-3.28), AMGN: 162.42 (-0.67)

Mylan Rises On Q3 Earnings Beat, Affirms Abbott Deal
at Investor's Business Daily - Fri Oct 31, 10:17AM CDT
Mylan (MYL) was up 3%, near 54, in early trading in the stock market today after the drugmaker beat Q3 estimates late Thursday. Earlier, the stock was up more than 7% at a nearly eight-month high above 56. Earnings came in on the high end of the...
ABT: 44.25 (+0.16), SHPG: 202.21 (+1.23), MYL: 53.51 (-0.44), ABBV: 63.85 (+0.06)

Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien
PR Newswire - Fri Oct 31, 8:05AM CDT
Investor-Edge has initiated coverage on the following equities: Medtronic Inc. (NYSE: MDT), Abbott Laboratories (NYSE: ABT), Hologic Inc. (NASDAQ: HOLX), ResMed Inc. (NYSE: RMD), and Covidien PLC (NYSE: COV). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 30, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,195.42, up 1.30% and the NASDAQ Composite closed at 4,566.14, up 0.37%. The S&P 500 finished the session 0.62% higher at 1,994.65. During the trading session, nine out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 774.91, up 1.81%, with the index gaining 7.78% in the previous three months. Register for your complimentary reports on these five stocks at:
ABT: 44.25 (+0.16), MDT: 68.99 (+0.28), COV: 93.71 (+0.07), RMD: 51.15 (+0.13), HOLX: 26.61 (+0.06)

Mylan Beats, Raises Earnings Guidance; Abbott Deal on Track - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:00AM CDT
Mylan (MYL) reported third quarter 2014 earnings of $1.16 per share.
MNK: 93.71 (+0.48), ABT: 44.25 (+0.16), ACT: 243.63 (-2.10), MYL: 53.51 (-0.44)

Clinical Trial Results, Product Approval Letter, Financial Results, and Upcoming Event - Research Reports on Receptos, Wright, United Therapeutics, Abbott and CareFusion
PR Newswire - Fri Oct 31, 7:40AM CDT
Today, Analysts Review released its research reports regarding Receptos Inc. (NASDAQ: RCPT), Wright Medical Group Inc. (NASDAQ: WMGI), United Therapeutics Corporation (NASDAQ: UTHR), Abbott Laboratories (NYSE: ABT) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7594-100free.
ABT: 44.25 (+0.16), WMGI: 28.18 (+0.21), CFN: 57.48 (-0.04), UTHR: 123.75 (-1.42), RCPT: 108.90 (-0.57), WMGIZ: 4.43 (+0.07)

Global Continuous Glucose Monitoring Market 2014-2018: Emerging Artificial Pancreas Technology
M2 - Fri Oct 31, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zk3lqw/global_continuous) has announced the addition of the "Global Continuous Glucose Monitoring Market 2014-2018" report to their offering. The Global Continuous Glucose Monitoring market to grow at a CAGR of 14.74% over the period 2013-2018 Continuous glucose monitoring is the measurement of glucose levels at regular intervals from a diabetic patient. Continuous glucose monitoring systems allow to gain insight into the trends of glucose levels between fingersticks, resulting in improved glucose control. Continuous glucose monitoring system comprises of a glucose sensor that is placed subcutaneously to provide the reading of glucose levels in tissue fluid. A transmitter sends information about the glucose levels using radio waves from the sensor to a receiver display. Continuous glucose monitoring system also offers additional information about HbA1C levels and fructosamine levels. The report covers the present scenario and the growth prospects of the Global Continuous Glucose Monitoring market for the period 2014-2018. In terms of component, the Global Continuous Glucose Monitoring market is divided into three segments: Transmitters and Receivers, Glucose Sensors, and Insulin Pumps. One key trend emerging in the market is the use of artificial pancreas technology in continuous glucose monitoring systems. The artificial pancreas is a closed-loop insulin delivery system that mimics the functions of a healthy pancreas in the human body by continuously monitoring glucose levels and automatically adjusting insulin delivery with minimal or no patient interaction. According to the report, one of the main drivers in this market is the rise in the incidence of diabetes across the population worldwide. Diabetes is also a cause of co-morbidities such as heart disease, stroke, kidney disease, blindness, and other debilitating diseases. The demand for continuous glucose monitoring has increased as diabetics look for ways to gain control over their glucose levels and manage them better. Further, the report states that one of the major challenges in the market is the presence of alternative methods of glucose monitoring. Blood glucose meters, test strips, and lancets, which are widely used in glucose monitoring products, can pose a hindrance to the adoption and growth in the popularity of continuous glucose monitoring systems. Key Vendors - Abbott Laboratories - Dexcom - Medtronic Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Product - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zk...continuous
ABT: 44.25 (+0.16), MDT: 68.99 (+0.28)

Strata Decision Technology is Named Winner of 13th Annual Chicago Innovation Award
PR Newswire - Thu Oct 30, 8:55PM CDT
Strata Decision Technology (Strata Decision) has been named one of the winners of the 13th annual Chicago Innovation Awards. The Company's cloud-based financial analytics and performance platform, StrataJazz®, is leveraged for financial planning, decision support, and continuous cost improvement by over 1,000 hospitals in the U.S.
ABT: 44.25 (+0.16)

Global Coagulation Testing Market 2014-2018 - Increase in Prevalence of CVD
M2 - Thu Oct 30, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdcwwv/global) has announced the addition of the "Global Coagulation Testing Market 2014-2018" report to their offering. Coagulation tests help in measuring the clotting ability of blood. Clotting is the process of blood converting from liquid into gel form. Coagulation tests are performed to analyze clotting disorders such as hemorrhage and thrombosis. Coagulation tests include complete blood count, factor V assay, fibrinogen level, prothrombin time, platelet count, thrombin time, and bleeding time. Coagulation testing analyzers play a major role in improving patients' quality of life. An expansion of some of the economies in the APAC region is one of the main trends seen in this market. Governments in emerging countries are making efforts to improve healthcare infrastructure, which has benefited the Coagulation Testing market. According to the report, one of the major drivers in the market is the increase in the prevalence of cardiovascular disease. CVD deaths occur almost equally in men and women and it is predicted that by 2030 almost 23.6 million people will die from CVD. An increase in the prevalence of CVD has led to the development of coagulation testing products, and thus, the growth of the market. Further, the report states that one of the major challenges in the market is the high cost incurred in R&D activities. Many big vendors are facing the frequent elimination of coagulation testing analyzer products because of rapid developments with respect to the technological aspects of coagulation testing analyzers. The Global Coagulation Testing market can be segmented into the revenue generated from end- user application such as: - Point-of-Care Coagulation Testing - Home Diagnostics Key Vendors - Abbott Laboratories - Danaher - F. Hoffmann-La Roche - Sysmex Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Coagulation Testing Application - Market Landscape - Market Segmentation by Technology - Market Segmentation by Types Coagulation Tests - Market Segmentation by End-users - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape For more information visit http://www.researchandmarkets.com/research/kdcwwv/global
ABT: 44.25 (+0.16), DHR: 81.41 (+0.12)

Abbott Labs Pays $250 Million for Topera in Heart Health Move
at The Street - Thu Oct 30, 8:12AM CDT
The buyer also acquired an option to purchase Advanced Cardiac Therapeutics, which is developing a novel ablation catheter.
ABT: 44.25 (+0.16), ACT: 243.63 (-2.10)

eBay Collaborates with Mario Wagner to Create ART FOR ALL - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 6:13PM CST
eBay Inc. (EBAY) recently entered into a partnership with artist Mario Wagner to create ART FOR ALL, an Interactive Art Installation in New York City.
ABTL: 10.57 (-0.12), EBAY: 54.19 (+0.30), MELI: 134.93 (-1.61), ZU: 29.09 (+0.26)

Wheel Deals for Veterans, From the Editors at Autobytel
GlobeNewswire - Mon Nov 10, 1:01PM CST
Autobytel Inc. (Nasdaq:ABTL), pioneer of the automotive Internet and the company dedicated to connecting automotive consumers with dealers, today highlighted notable new car savings programs for veterans, reservists, and retired and active-duty military personnel in honor of Veterans Day.
ABTL: 10.57 (-0.12)

Microsemi Tops Q4 Earnings on High Volume; Favorable View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:20AM CST
Microsemi Corporation's (MSCC) adjusted earnings in the fourth quarter of fiscal 2014 of 56 cents per share exceeded the Zacks Consensus Estimate by 4 cents due to higher volume which resulted in stronger revenues.
ABTL: 10.57 (-0.12), MSCC: 27.13 (+0.09), MELI: 134.93 (-1.61), ZU: 29.09 (+0.26)

Autobytel (ABTL) Jumps: Stock Adds 7.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:37AM CST
Autobytel Inc. (ABTL) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
ABTL: 10.57 (-0.12), STMP: 46.53 (+2.37), MELI: 134.93 (-1.61), ZU: 29.09 (+0.26)

Netflix to Enter Australia by 2015, Boosts Overseas Business - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 4:40PM CST
Netflix, Inc. (NFLX) is reportedly set to hit the Australian market in 2015 with the launch of its services.
NFLX: 382.55 (-4.72), ABTL: 10.57 (-0.12), MELI: 134.93 (-1.61), NWS: 14.92 (-0.02)

Nasdaq stocks posting largest percentage increases
AP - Thu Nov 06, 12:17PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
ESYS: 17.32 (-0.02), SWIR: 36.09 (+0.29), PERI: 5.88 (+0.06), JIVE: 6.62 (+0.18), TREE: 48.01 (+0.29), KERX: 15.94 (-0.49), ECYT: 6.25 (+0.07), ADEP: 9.06 (+0.71), ABTL: 10.57 (-0.12), NDLS: 23.86 (-0.71), BSFT: 27.34 (-0.43), SW.TO: 40.88 (+0.12), CALD: 15.93 (+0.06), PLNR: 6.81 (-0.87)

Shares of ABTL Down 18.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Nov 06, 9:17AM CST
SmarTrend identified a Downtrend for Autobytel (NASDAQ:ABTL) on July 17th, 2014 at $12.04. In approximately 4 months, Autobytel has returned 18.40% as of today's recent price of $9.82.
ABTL: 10.57 (-0.12)

Autobytel (ABTL) CEO Jeff Coats on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 7:20PM CST

ABTL: 10.57 (-0.12)

Autobytel Reports 26% Increase in Revenues for 2014 Third Quarter
GlobeNewswire - Wed Nov 05, 3:36PM CST
Autobytel Inc. (Nasdaq:ABTL), pioneer of the automotive Internet and the company dedicated to connecting automotive consumers with dealers, today reported continued improvement in its financial results for the third quarter and nine-months ended September 30, 2014.
ABTL: 10.57 (-0.12)

Autobytel beats by $0.12, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:26PM CST

ABTL: 10.57 (-0.12)

Alibaba Group (BABA) Lags Q2 Earnings on High Expenses - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:40AM CST
Alibaba Group Holding Limited (BABA) reported second-quarter fiscal 2015 (ended Sep 30, 2014) earnings of 25 cents per share, missing the Zacks Consensus Estimate of 37 cents due to increased investments in mobile, marketing and other new ventures.
ABTL: 10.57 (-0.12), MELI: 134.93 (-1.61), ZU: 29.09 (+0.26), BABA: 114.54 (-4.61)

Office Depot, Inc. (ODP) in Focus: Stock Soars 24.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:21AM CST
Office Depot, Inc. (ODP) was a big mover last session, as the company saw its shares rise by almost 25% on the day.
ABTL: 10.57 (-0.12), BBW: 18.42 (+0.42), ODP: 6.66 (+0.17), BKS: 22.55 (+0.05)

Notable earnings after Wednesday’s close
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:35PM CST

CXO: 116.43 (+0.85), CODI: 17.16 (-1.14), EXXI: 6.97 (-0.05), JCOM: 56.34 (+0.59), ATSG: 8.49 (-0.16), GPOR: 53.97 (+0.50), ENS: 60.15 (-0.12), ECYT: 6.25 (+0.07), ALNY: 98.47 (-0.71), KGC: 2.42 (+0.08), GSM: 18.73 (+0.02), BKD: 32.87 (-0.21), DK: 30.89 (-0.29), AR: 55.06 (+0.28), IL: 9.39 (+0.30), DVR: 0.14 (-0.08), IO: 2.99 (+0.26), DEPO: 14.42 (-0.13), ETE: 62.04 (+0.06), AVG: 19.46 (-0.13), CSOD: 29.06 (+0.29), GNW: 8.40 (+0.28), ECOL: 44.02 (unch), BWC: 30.15 (-0.25), CPE: 6.13 (+0.07), FNV: 50.71 (+2.85), CTL: 39.97 (+0.13), ASH: 112.72 (+1.04), ENSG: 40.63 (unch), CLR: 54.92 (+0.70), ACAS: 15.51 (unch), G: 18.03 (+0.10), BREW: 13.68 (-0.15), AWK: 52.72 (-0.15), CVG: 21.34 (-0.12), AREX: 11.05 (+0.44), HTCH: 3.63 (-0.07), ETP: 65.07 (-0.30), ABTL: 10.57 (-0.12), FMI: 24.48 (-0.23), DPM: 51.15 (-1.12), BCOR: 14.52 (-0.18), CDE: 3.86 (+0.28), DRYS: 1.45 (-0.02), KW: 27.87 (-0.03), BALT: 3.24 (-0.03), ATO: 54.24 (-0.06), EXAR: 8.78 (+0.19), ACLS: 2.15 (unch), INWK: 7.56 (-0.08), ALSK: 1.34 (-0.11), CF: 266.81 (+12.41), EFC: 21.86 (-0.11), BIOS: 5.73 (+0.14), DYN: 34.70 (+0.21), DATA: 84.05 (+0.50), ANDE: 54.54 (-0.23), HOLX: 26.61 (+0.06), CBS: 51.84 (-0.29)

Blue Nile Inc. (NILE) in Focus: Stock Soars 13.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:21AM CDT
Blue Nile Inc. (NILE) was a big mover last session, as the company saw its shares rise by about 14% on the day.
ABTL: 10.57 (-0.12), NILE: 36.30 (+0.71), IACI: 65.75 (-0.16), OWW: 7.62 (+0.07)

Downtrend Call Working As Autobytel Stock Falls 26.7% (ABTL)
Comtex SmarTrend(R) - Wed Oct 29, 4:54PM CDT
SmarTrend identified a Downtrend for Autobytel (NASDAQ:ABTL) on July 17th, 2014 at $12.04. In approximately 3 months, Autobytel has returned 26.71% as of today's recent price of $8.82.
ABTL: 10.57 (-0.12)

Maxim Integrated Beats on Q1 Earnings, Misses Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 8:40AM CDT
Maxim Integrated Products, Inc.'s (MXIM) first quarter fiscal 2015 adjusted earnings of 38 cents per share beat the Zacks Consensus Estimate by a penny.
MXIM: 29.49 (-0.22), ABTL: 10.57 (-0.12), XWES: 5.45 (+0.01), ZU: 29.09 (+0.26)

Ingram Micro (IM) Rises: Stock Moves 6.4% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 7:57AM CDT
Ingram Micro Inc. (IM) was a big mover last session, as the company saw its shares rise over 6% on the day.
ABTL: 10.57 (-0.12), IM: 26.72 (-0.15), BBW: 18.42 (+0.42), ARO: 2.77 (-0.14)

Falling Earnings Estimates Signal Weakness Ahead for Netflix (NFLX) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 7:49AM CDT
Netflix (NFLX) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter as well as the current year.
NFLX: 382.55 (-4.72), ABTL: 10.57 (-0.12), STMP: 46.53 (+2.37), OSTK: 24.30 (+0.10)

Amazon Slumps: AMZN Tumbles 8.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 7:37AM CDT
Amazon has been witnessing a mixed trend in its current year estimate revision and its share price has been declining for past 1 month
AMZN: 312.01 (+6.90), ABTL: 10.57 (-0.12), STMP: 46.53 (+2.37), OSTK: 24.30 (+0.10)

Lam Research Beats on Q1 Earnings, Revenues Increase Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 12:00PM CDT
Lam Research Corporation (LRCX) reported first quarter fiscal 2015 non-GAAP earnings of 96 cents per share, which beat the Zacks Consensus Estimate by 3 cents
ABTL: 10.57 (-0.12), LRCX: 79.98 (+0.06), XWES: 5.45 (+0.01), OWW: 7.62 (+0.07)